search
Back to results

Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve (ROAD-IFR)

Primary Purpose

Ischemic Heart Disease

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
roadmap
iFR/FFR
Sponsored by
Yonsei University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemic Heart Disease focused on measuring iFR/FFR, Roadmap

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients aged 19 years or older Patients with stable angina, including asymptomatic ischemic heart disease, who have 50-90% stenosis of the causative vessel by coronary angiography Acute coronary syndrome patients with multivessel disease and 50-90% stenosis of non-caused vessels that did not cause acute coronary syndrome Patients who voluntarily decided to participate in this study and gave written consent to the subject consent form Exclusion Criteria: Patients with acute coronary syndrome and single vessel disease Patients who have undergone previous coronary artery bypass grafting Poor coronary blood flow (TIMI grade ≤ 2) If life expectancy is less than one year Women who are pregnant or wish to become pregnant

Sites / Locations

  • Yongcheol KimRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

tested using the roadmap system

tested without using the roadmap system

Arm Description

tested using the roadmap system

tested without using the roadmap system.

Outcomes

Primary Outcome Measures

iFR time
iFR time: the time interval between the pressure wire into the guiding catheter and the placement of the pressure wire on the distal of the blood vessel to measure iFR
FFR time
FFR time: the time interval between the equalization of the pressure wire for FFR and the placement of the pressure wire on the distal of the blood vessel to measure FFR

Secondary Outcome Measures

Success rate of placement of the pressure wire on the distal of the blood vessel to measure iFR/FFR
The success rate of advancing pressure wire to a target vessel distally
Use of contrast medium until the pressure wire is advanced to the distal end of the blood vessel
Use of contrast medium until the pressure wire is advanced to the distal end of the blood vessel
The amount of contrast medium used until the pressure wire is advanced to the distal end of the blood vessel
The amount of contrast medium used until the pressure wire is advanced to the distal end of the blood vessel
Total procedure time to assess functional significance using iFR/FFR pressure wire
Total procedure time between insertion and out of guiding catheter via a sheath
Total procedure time
Total procedure time
Total amount of contrast media usage
Total amount of contrast media usage
Total dose of radiation exposure
Total dose of radiation exposure
Complications related to the procedure
Complications related to the procedure

Full Information

First Posted
December 27, 2022
Last Updated
August 2, 2023
Sponsor
Yonsei University
Collaborators
Philips Healthcare
search

1. Study Identification

Unique Protocol Identification Number
NCT05682118
Brief Title
Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve
Acronym
ROAD-IFR
Official Title
Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve: A Single-Center, Randomized Study (ROAD-IFR Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2023 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
November 27, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Yonsei University
Collaborators
Philips Healthcare

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In patients with 50-90% stenosis of the coronary artery, the coronary roadmap (dynamic roadmap) is performed when the conventional fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are performed. coronary roadmap system) to confirm the effectiveness of the function.
Detailed Description
In coronary angiography, 50% or more stenosis of the causative vessel is observed in a patient with stable angina pectoris (SAP) or 50% or more stenosis of a non-causative vessel is observed in acute coronary syndrome (ACS) Based on 0.90, if it is less than 0.89, PCI is performed, and if it is 0.90 or more, drug treatment is performed. When the pressure wire tests are performed, the pressure wire is inserted from the origin of the blood vessel through the lesion to the distal portion, and the pressure wire is placed at the distal end of the blood vessel for measurement. In this process, there are many cases where the pressure wire escapes the branch blood vessel or does not pass through well. It takes a long time to stand up and evaluate stenosis, and in many cases, an additional contrast medium is used to additionally check blood vessel travel and to check the position and condition of the pressure wire. To overcome this, the software roadmap installed in the cardiac fluoroscopy device of the cardiac catheterization room can be helpful. However, there are currently no studies related to roadmaps in coronary artery examination. Therefore, in this study, we want to evaluate the effectiveness of the roadmap when examining FFR and iFR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Heart Disease
Keywords
iFR/FFR, Roadmap

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The sample size was calculated using effect size (Cohen's d) for the effectiveness of the dynamic coronary roadmap system for the guidance of the iFR and FFR. The effect size was assumed to be 0.4, which is a small to medium effect size. The sample size of 113 participants for each group was estimated to provide 90% power with a 2-sided type I error of 0.05. This is a single-center randomized study and will be conducted in 226 patients with 50-90% coronary artery stenosis on angiography. Afterward, randomly assigned, 113 patients will be tested using the roadmap system, and 113 patients will be tested without using the roadmap system. Methods for measuring FFR and iFR and all PCI will use standardized testing and procedure methods.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
226 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
tested using the roadmap system
Arm Type
Experimental
Arm Description
tested using the roadmap system
Arm Title
tested without using the roadmap system
Arm Type
Active Comparator
Arm Description
tested without using the roadmap system.
Intervention Type
Procedure
Intervention Name(s)
roadmap
Intervention Description
FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Intervention Type
Procedure
Intervention Name(s)
iFR/FFR
Intervention Description
Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Primary Outcome Measure Information:
Title
iFR time
Description
iFR time: the time interval between the pressure wire into the guiding catheter and the placement of the pressure wire on the distal of the blood vessel to measure iFR
Time Frame
Through procedure completion, up to 24 hours
Title
FFR time
Description
FFR time: the time interval between the equalization of the pressure wire for FFR and the placement of the pressure wire on the distal of the blood vessel to measure FFR
Time Frame
Through procedure completion, up to 24 hours
Secondary Outcome Measure Information:
Title
Success rate of placement of the pressure wire on the distal of the blood vessel to measure iFR/FFR
Description
The success rate of advancing pressure wire to a target vessel distally
Time Frame
Through procedure completion, up to 24 hours
Title
Use of contrast medium until the pressure wire is advanced to the distal end of the blood vessel
Description
Use of contrast medium until the pressure wire is advanced to the distal end of the blood vessel
Time Frame
Through procedure completion, up to 24 hours
Title
The amount of contrast medium used until the pressure wire is advanced to the distal end of the blood vessel
Description
The amount of contrast medium used until the pressure wire is advanced to the distal end of the blood vessel
Time Frame
Through procedure completion, up to 24 hours
Title
Total procedure time to assess functional significance using iFR/FFR pressure wire
Description
Total procedure time between insertion and out of guiding catheter via a sheath
Time Frame
Through procedure completion, up to 24 hours
Title
Total procedure time
Description
Total procedure time
Time Frame
Through procedure completion, up to 24 hours
Title
Total amount of contrast media usage
Description
Total amount of contrast media usage
Time Frame
Through procedure completion, up to 24 hours
Title
Total dose of radiation exposure
Description
Total dose of radiation exposure
Time Frame
Through procedure completion, up to 24 hours
Title
Complications related to the procedure
Description
Complications related to the procedure
Time Frame
Through procedure completion, up to 24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 19 years or older Patients with stable angina, including asymptomatic ischemic heart disease, who have 50-90% stenosis of the causative vessel by coronary angiography Acute coronary syndrome patients with multivessel disease and 50-90% stenosis of non-caused vessels that did not cause acute coronary syndrome Patients who voluntarily decided to participate in this study and gave written consent to the subject consent form Exclusion Criteria: Patients with acute coronary syndrome and single vessel disease Patients who have undergone previous coronary artery bypass grafting Poor coronary blood flow (TIMI grade ≤ 2) If life expectancy is less than one year Women who are pregnant or wish to become pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yongcheol Kim, MD, PhD
Phone
+823151898967
Email
yongcheol@yuhs.ac
First Name & Middle Initial & Last Name or Official Title & Degree
Ji Woong Roh, MD, PhD
Phone
+823151898792
Email
NOMGALDA@yuhs.ac
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yongcheol Kim, MD, PhD
Organizational Affiliation
Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yongcheol Kim
City
Yongin
State/Province
Gyeonggi-do
ZIP/Postal Code
16995
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongcheol Kim, MD
Phone
+823151898967
Email
yongcheol@yuhs.ac
First Name & Middle Initial & Last Name & Degree
Yongcheol Kim, MD, PhD
First Name & Middle Initial & Last Name & Degree
Oh-Hyun Lee, MD
First Name & Middle Initial & Last Name & Degree
Ji Woong Roh, MD, PhD
First Name & Middle Initial & Last Name & Degree
Eui Im, MD
First Name & Middle Initial & Last Name & Degree
Deok-Kyu Cho, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve

We'll reach out to this number within 24 hrs